More color on Cepheid Q1 results

|By:, SA News Editor

Total top line sales were $106.9M, up 16% yoy. Clinical Systems revenues were $17.3M (+38%) and Clinical Reagents revenues were $83.1M (+24%).

The North America business fell slightly (-1%) while the International business grew 56%.

Net loss was -$0.13/share compared to breakeven a year ago.

503 GeneXpert systems placed globally.

GAAP gross margin was 50% compared to 53% yoy.

2014 guidance range for revenues is $446M - $461M with a loss/share between -$0.38 and -$0.43.

(CPHD +0.7%)